Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
PSNL 
Personalis Inc (PSNL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/14/2025: PSNL (4-star) is a STRONG-BUY. BUY since 47 days. Profits (61.75%). Updated daily EoD!
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $7
1 Year Target Price $7
| 4 | Strong Buy |
| 2 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 96.4% | Avg. Invested days 30 | Today’s Advisory Regular Buy |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 07/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 562.63M USD | Price to earnings Ratio - | 1Y Target Price 7 |
Price to earnings Ratio - | 1Y Target Price 7 | ||
Volume (30-day avg) 7 | Beta 1.87 | 52 Weeks Range 1.62 - 7.79 | Updated Date 07/14/2025 |
52 Weeks Range 1.62 - 7.79 | Updated Date 07/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.29 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -98.1% | Operating Margin (TTM) -85.88% |
Management Effectiveness
Return on Assets (TTM) -17.9% | Return on Equity (TTM) -51.25% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 421361129 | Price to Sales(TTM) 6.57 |
Enterprise Value 421361129 | Price to Sales(TTM) 6.57 | ||
Enterprise Value to Revenue 4.92 | Enterprise Value to EBITDA -0.03 | Shares Outstanding 88325104 | Shares Floating 52244319 |
Shares Outstanding 88325104 | Shares Floating 52244319 | ||
Percent Insiders 31.49 | Percent Institutions 46.11 |
Upturn AI SWOT
Personalis Inc
Company Overview
History and Background
Personalis, Inc. was founded in 2011 and went public in 2019. It is a precision oncology company transforming the development of next-generation cancer therapies. Personalis focuses on providing comprehensive genomic profiling services to enable the development of more effective cancer treatments.
Core Business Areas
- NeXT Platform: The NeXT Platform is Personalis's core offering, providing comprehensive genomic profiling from tissue and liquid biopsies. It analyzes all ~20,000 human genes, plus the immune system, from a single sample.
- Neoantigen Discovery: Personalis leverages its platform to discover neoantigens, unique markers on cancer cells, which can be targeted by immunotherapies.
- Companion Diagnostics: Personalis develops companion diagnostics to identify patients most likely to respond to specific cancer therapies.
Leadership and Structure
Personalis is led by CEO Chris Hall and has a management team with experience in genomics, diagnostics, and biotechnology. The company operates with a focus on research and development, clinical testing services, and pharmaceutical partnerships.
Top Products and Market Share
Key Offerings
- NeXT Platform: This platform is Personalis's flagship product, offering whole-exome and transcriptome sequencing for cancer research and clinical trials. While specific market share data is not readily available due to the fragmented nature of the precision oncology market, Personalis competes with companies like Illumina (ILMN) and Foundation Medicine (FMI, acquired by Roche). Revenue is significantly generated through partnerships with pharmaceutical companies and academic institutions. The company does not generally disclose revenue figures for individual products.
Market Dynamics
Industry Overview
The precision oncology industry is rapidly growing, driven by advancements in genomic sequencing and personalized medicine. This includes companies offering next generation sequencing (NGS) panels, whole exome sequencing and RNA sequencing, and personalized cancer vaccines, and companion diagnostics.
Positioning
Personalis positions itself as a leader in comprehensive genomic profiling for cancer, particularly in the areas of immunotherapy development and biomarker discovery. Its competitive advantage lies in its NeXT Platform's ability to analyze the entire genome and immune system.
Total Addressable Market (TAM)
The TAM for precision oncology is estimated to be in the tens of billions of dollars. Personalis is positioned to capture a significant portion of this market by providing comprehensive genomic profiling services to pharmaceutical companies developing novel cancer therapies.
Upturn SWOT Analysis
Strengths
- Comprehensive genomic profiling platform (NeXT)
- Expertise in neoantigen discovery
- Partnerships with leading pharmaceutical companies
- Strong research and development capabilities
Weaknesses
- Reliance on pharmaceutical partnerships
- Relatively small size compared to larger competitors
- Negative profitability
- High operating expenses
Opportunities
- Expanding into new therapeutic areas
- Developing companion diagnostics for more therapies
- Growing demand for personalized cancer treatments
- Expansion into international markets
Threats
- Competition from larger genomics companies
- Regulatory hurdles for companion diagnostics
- Pricing pressures from healthcare providers
- Technological advancements rendering current platforms obsolete
Competitors and Market Share
Key Competitors
- ILMN
- ROCHE.SW
Competitive Landscape
Personalis faces strong competition from larger, more established genomics companies like Illumina and Roche/Foundation Medicine. However, its comprehensive genomic profiling platform and focus on neoantigen discovery provide a competitive edge.
Growth Trajectory and Initiatives
Historical Growth: Personalis's growth has been uneven, with revenue fluctuations based on project milestones and pharmaceutical partnerships.
Future Projections: Future growth depends on securing new partnerships and the success of its NeXT Platform in clinical trials.
Recent Initiatives: Personalis has focused on expanding its partnerships with pharmaceutical companies to develop novel cancer therapies and companion diagnostics.
Summary
Personalis is a precision oncology company with a potentially promising technology platform for personalized cancer treatments, particularly within immunotherapeutics. However, it faces significant challenges, including financial instability, reliance on pharmaceutical partnerships, and fierce competition within the genomics industry. Its success hinges on securing and maintaining lucrative partnerships and demonstrating clinical utility of its platform. The company is delisted from the stock exchange and struggling.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Industry Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market share estimates are based on available data and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Personalis Inc
Exchange NASDAQ | Headquaters Fremont, CA, United States | ||
IPO Launch date 2019-06-20 | President, CEO & Director Mr. Christopher M. Hall | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 228 | Website https://www.personalis.com |
Full time employees 228 | Website https://www.personalis.com | ||
Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD), therapy response and recurrence monitoring in solid tumor cancers; and ImmunoID NeXT, a tissue-based service that combines whole exome and whole transcriptome sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for the detection of MRD; and NeXT Dx, a tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. In addition, the company performs whole exome sequencing of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing on human samples for research projects, such as population sequencing initiatives. Its services are used by pharmaceutical companies for translational research, biomarker discovery, the development of personalized cancer therapies, and for clinical trials, as well as tests are used by physicians to detect residual or recurrent cancer in patients, monitor cancer response to therapy, and uncover insights for therapy selection. The company's customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. Personalis, Inc. was incorporated in 2011 and is headquartered in Fremont, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.